Does Oral Medication (Gilenya) for Multiple Sclerorsis Cause Macular Edema?
October 13, 2011
Patients taking a new medication for multiple sclerosis, Gilenya (Fingolimod, Novartis) were found, in a 2 year trial, to have a 0.4% rate of macular edema compared to 0.1% in the control group. Those with a history of uveitis had a 20% rate; those without had a 0.5% rate. Researchers warn that uveitis patients especially need to watched carefully for this complication. Whether to discontinue this life-saving medication has to decided on a case-by-case basis.
You might also enjoy...
- How High is the Incidence of Retinal Breaks in 25g Macular Surgery?
- Is There A Benefit to Cataract Surgery in Patients with Alzhemier’s Disease?
- Can Salvage Radiotherapy Preserve Useful Vision in Bilateral Retinoblastoma?
- Can Thrombolytic Therapy Improve Vision in Patients With CRVO?
- Intravitreal Avastin® (bevacizumab) for Diffuse DME: The Pan-American Collaborative Retina Study Group at 24 Months
Comments
Jump down to form below to submit your own comments
Thanks for this health alert! Real informative post.
Best Regards,
Monterey Park Optometry